J&J's MajesTEC-3 Data Creates Competitive Landscape in Multiple Myeloma Treatment

Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.